The Experts below are selected from a list of 22719 Experts worldwide ranked by ideXlab platform
Anthony Miliotto - One of the best experts on this subject based on the ideXlab platform.
-
epigenetic potentiation of ny eso 1 Vaccine Therapy in human ovarian cancer
Cancer immunology research, 2014Co-Authors: Kunle Odunsi, Junko Matsuzaki, Smitha R James, Paulette Mhawechfauceglia, Takemasa Tsuji, Austin Miller, Wa Zhang, S N Akers, Elizabeth A Griffiths, Anthony MiliottoAbstract:The cancer-testis/cancer-germline antigen NY-ESO-1 is a Vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to Vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase (DNMT) inhibitors may augment NY-ESO-1 Vaccine Therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Pre-clinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1-specific CTL-mediated responses. Based on these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 Vaccine and doxorubicin liposome (doxorubicin) chemoTherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in 6/10 evaluable patients. Based on these encouraging results, evaluation of similar combinatorial chemo-immunoTherapy regimens in EOC and other tumor types is warranted.
-
epigenetic potentiation of ny eso 1 Vaccine Therapy in human ovarian cancer
Cancer immunology research, 2014Co-Authors: Kunle Odunsi, Junko Matsuzaki, Smitha R James, Paulette Mhawechfauceglia, Takemasa Tsuji, Austin Miller, Wa Zhang, S N Akers, Elizabeth A Griffiths, Anthony MiliottoAbstract:The cancer–testis/cancer germline antigen, NY-ESO-1, is a Vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to Vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase inhibitors may augment NY-ESO-1 Vaccine Therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Preclinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1–specific CTL-mediated responses. On the basis of these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 Vaccine and doxorubicin liposome chemoTherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T-cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in six of ten evaluable patients. On the basis of these encouraging results, evaluation of similar combinatorial chemo-immunoTherapy regimens in EOC and other tumor types is warranted. Cancer Immunol Res; 2(1); 37–49. ©2014 AACR .
Shaoli Liu - One of the best experts on this subject based on the ideXlab platform.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA ‘locking strands’ outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge. A DNA nanodevice Vaccine has been developed and utilized to stimulate a tumour-specific cytotoxic T lymphocyte response in vivo, leading to the inhibition of tumour growth as well as prevention of metastasis.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA 'locking strands' outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.
Yingxu Shang - One of the best experts on this subject based on the ideXlab platform.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA ‘locking strands’ outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge. A DNA nanodevice Vaccine has been developed and utilized to stimulate a tumour-specific cytotoxic T lymphocyte response in vivo, leading to the inhibition of tumour growth as well as prevention of metastasis.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA 'locking strands' outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.
Kunle Odunsi - One of the best experts on this subject based on the ideXlab platform.
-
epigenetic potentiation of ny eso 1 Vaccine Therapy in human ovarian cancer
Cancer immunology research, 2014Co-Authors: Kunle Odunsi, Junko Matsuzaki, Smitha R James, Paulette Mhawechfauceglia, Takemasa Tsuji, Austin Miller, Wa Zhang, S N Akers, Elizabeth A Griffiths, Anthony MiliottoAbstract:The cancer-testis/cancer-germline antigen NY-ESO-1 is a Vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to Vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase (DNMT) inhibitors may augment NY-ESO-1 Vaccine Therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Pre-clinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1-specific CTL-mediated responses. Based on these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 Vaccine and doxorubicin liposome (doxorubicin) chemoTherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in 6/10 evaluable patients. Based on these encouraging results, evaluation of similar combinatorial chemo-immunoTherapy regimens in EOC and other tumor types is warranted.
-
epigenetic potentiation of ny eso 1 Vaccine Therapy in human ovarian cancer
Cancer immunology research, 2014Co-Authors: Kunle Odunsi, Junko Matsuzaki, Smitha R James, Paulette Mhawechfauceglia, Takemasa Tsuji, Austin Miller, Wa Zhang, S N Akers, Elizabeth A Griffiths, Anthony MiliottoAbstract:The cancer–testis/cancer germline antigen, NY-ESO-1, is a Vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to Vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase inhibitors may augment NY-ESO-1 Vaccine Therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of circulating antibodies to NY-ESO-1. Preclinical studies using EOC cell lines showed that decitabine treatment enhanced both NY-ESO-1 expression and NY-ESO-1–specific CTL-mediated responses. On the basis of these observations, we performed a phase I dose-escalation trial of decitabine, as an addition to NY-ESO-1 Vaccine and doxorubicin liposome chemoTherapy, in 12 patients with relapsed EOC. The regimen was safe, with limited and clinically manageable toxicities. Both global and promoter-specific DNA hypomethylation occurred in blood and circulating DNAs, the latter of which may reflect tumor cell responses. Increased NY-ESO-1 serum antibodies and T-cell responses were observed in the majority of patients, and antibody spreading to additional tumor antigens was also observed. Finally, disease stabilization or partial clinical response occurred in six of ten evaluable patients. On the basis of these encouraging results, evaluation of similar combinatorial chemo-immunoTherapy regimens in EOC and other tumor types is warranted. Cancer Immunol Res; 2(1); 37–49. ©2014 AACR .
Yiming Wang - One of the best experts on this subject based on the ideXlab platform.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA ‘locking strands’ outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge. A DNA nanodevice Vaccine has been developed and utilized to stimulate a tumour-specific cytotoxic T lymphocyte response in vivo, leading to the inhibition of tumour growth as well as prevention of metastasis.
-
a dna nanodevice based Vaccine for cancer immunoTherapy
Nature Materials, 2021Co-Authors: Shaoli Liu, Qiao Jiang, Xiao Zhao, Ruifang Zhao, Yuanning Wang, Yiming Wang, Jianbing Liu, Yingxu ShangAbstract:A major challenge in cancer Vaccine Therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we describe a structurally well defined DNA nanodevice Vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA 'locking strands' outside the nanostructures enables the opening of the Vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response. The DNA nanodevice Vaccine elicited a potent antigen-specific T-cell response, with subsequent tumour regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumour rechallenge.